1,783 reports of this reaction
1.6% of all UPADACITINIB reports
#11 most reported adverse reaction
THERAPY INTERRUPTED is the #11 most commonly reported adverse reaction for UPADACITINIB, manufactured by AbbVie Inc.. There are 1,783 FDA adverse event reports linking UPADACITINIB to THERAPY INTERRUPTED. This represents approximately 1.6% of all 110,317 adverse event reports for this drug.
UPADACITINIB has an overall safety score of 85 out of 100. Patients taking UPADACITINIB who experience therapy interrupted should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPY INTERRUPTED is a less commonly reported adverse event for UPADACITINIB, but still significant enough to appear in the safety profile.
In addition to therapy interrupted, the following adverse reactions have been reported for UPADACITINIB:
The following drugs have also been linked to therapy interrupted in FDA adverse event reports:
THERAPY INTERRUPTED has been reported as an adverse event in 1,783 FDA reports for UPADACITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPY INTERRUPTED accounts for approximately 1.6% of all adverse event reports for UPADACITINIB, making it a notable side effect.
If you experience therapy interrupted while taking UPADACITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.